Role of Subclinical Iatrogenic Hyperthyroidism in the Setting of Heart Disease and Arrhythmic Burden

Author(s): Sandra Mastroianno, Giuseppe Di Stolfo*, Angela Maggio, Michele Pacilli, Domenico Rosario Potenza, Raimondo Massaro, Giovanni De Luca, Aldo Russo.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Volume 20 , Issue 6 , 2020

Become EABM
Become Reviewer

Abstract:

Background: Subclinical hyperthyroidism is defined by a subnormal serum thyroidstimulating hormone (TSH) level with normal free thyroxine (FT4) and free triiodothyronine (FT3) levels. Its prevalence varies from 0.6% to 16% in the elderly and can increase to 20% in patients receiving thyroid hormone replacement therapy. Thyroid disease and/or replacement therapy are frequently associated with cardiovascular involvement.

Cases Presentation: We report three clinical cases of patients with initial subclinical hyperthyroidism and cardiological manifestations, including supraventricular and ventricular extrasystoles, prolapse of the mitral valve with severe regurgitation, higher mean heart rate and deterioration of the arrhythmias on arrhythmogenic dysplasia substrate.

Conclusion: We discuss the role of appropriate and early correction of thyroid dysfunction in improving cardiological manifestations.

Keywords: Subclinical hyperthyroidism, heart disease, arrhythmia, mitral valve insufficiency, accessory pathway, l-thyroxine.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 6
Year: 2020
Page: [959 - 962]
Pages: 4
DOI: 10.2174/1871530320666191227103627
Price: $95

Article Metrics

PDF: 7